Literature DB >> 16634243

Descriptive epidemiology of hepatitis C virus among male heroin abusers in Taiwan.

Kuan-Fu Liao1, Chen-Yuang Peng, Shih-Wei Lai, Wu-Long Chang, Nan-Yung Hsu.   

Abstract

BACKGROUND: The purpose of this study was to explore the epidemiology of hepatitis C virus (HCV) infection and to determine the risk factors for HCV infection among heroin abusers in Taiwan.
METHODS: This was a cross-sectional study. From November 2004 to February 2005, 577 subjects, including 423 subjects (73.3%) using injectable heroin and 154 subjects (26.7%) using smoked heroin from one male prison located in Taiwan, were enrolled in this study. The mean age was 33.3 +/- 7.9 years (age range 19-65 years). Anti-HCV antibody was tested. A face-to-face interview focusing on sociodemographic information and risk behaviors was addressed. The t test, chi-squared test, and multivariate logistic regression were used.
RESULTS: The overall prevalence of anti-HCV antibody positivity was 74.9%, with 89.8% among injecting heroin abusers and 33.8% among smoking heroin abusers (P < 0.0001). The multivariate logistic regression analysis demonstrated that needle sharing was independently related to HCV infection (odds ratio = 5.25, 95% confidence interval = 2.48-11.12).
CONCLUSIONS: The prevalence of anti-HCV antibody positivity among male injecting drug abusers is high in Taiwan. Needle sharing is identified as a potential risk factor for HCV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16634243     DOI: 10.1097/01.smj.0000209284.33650.45

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

Review 1.  Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors:  Amedeo Lonardo; Paola Loria; Nicola Carulli
Journal:  Intern Emerg Med       Date:  2008-02-15       Impact factor: 3.397

Review 2.  Controversies in and challenges to our understanding of hepatitis C.

Authors:  Robert G Batey
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.